ONC8027 : Cancer Drug Development and Innovative therapies (E-learning)
- Offered for Year: 2020/21
- Module Leader(s): Mr Steve Williamson
- Lecturer: Mrs Jude Heed
- Owning School: FMS Graduate School
- Teaching Location: Newcastle City Campus
|Semester 2 Credit Value:||10|
This module looks at how new cancer medicines are developed, marketed and introduced into clinical practice. The wider context of the impact new concepts in personalized health care and new medicine technologies will be evaluated, including CAR-T and novel biological therapies
Outline Of Syllabus
• Product Development 1:-Challenges, Barriers and Benefits.
• Product Development 2: Phase I/II/III/IV trials are they still relevant?
• Product Development 3 New Models of clinical drug development
• Innovation 1: Personalized Medicine and Biomarkers
• Innovation 2: New therapies and Biosimilars
• Innovation 3: CAR-T and cellular therapies: Part 1
• Innovation 4: CAR-T and cellular therapies: Part 2
• Innovation 5: Tumour Agnostic Treatments
• Marketing and Promotion payer, provider and clinician perspective to prescribers
• Models of Joint Working between industry and healthcare systems
Please note that module leaders are reviewing the module teaching and assessment methods for Semester 2 modules, in light of the Covid-19 restrictions. There may also be a few further changes to Semester 1 modules. Final information will be available by the end of August 2020 in for Semester 1 modules and the end of October 2020 for Semester 2 modules.
|Guided Independent Study||Assessment preparation and completion||2||10:00||20:00||Independent assessment preparation|
|Guided Independent Study||Directed research and reading||12||3:00||36:00||Online content|
|Guided Independent Study||Reflective learning activity||12||2:00||24:00||Reflective Online Journal|
|Guided Independent Study||Independent study||8||1:00||8:00||Supplemental reading|
|Guided Independent Study||Online Discussion||12||1:00||12:00||Via online discussion board|
Teaching Rationale And Relationship
Through a series of online tutorials and weekly activities as well as private study (including directed reading) students will gain a detailed knowledge of understanding of how cancer medicines reach patients in the ‘real world’, gain insight into the development and use of innovative technologies and understand challenges faced by health systems in introducing these medicines.
Students are encouraged to participate in online collaborative discussions via the discussion boards so they can help debate current practices and the reflective journal will help to consolidate their understanding of the curriculum.
Student's responses to the activities will be posted on the discussion board on blackboard (used for online discussion) to foster dialogue between students and the instructors. The instructors will monitor and comment on all student responses to the activities to help with the consolidation of
knowledge and understanding of the learning outcomes.
The format of resits will be determined by the Board of Examiners
|Essay||2||M||90||One essay question (2000 words).|
|Portfolio||2||M||10||Participation in collaborative e-learning activities throughout the module.|
|Written Examination||2||M||New technology implementation Exercise|
Assessment Rationale And Relationship
This assessment strategy is designed to allow the students' to demonstrate a depth of knowledge in a focused topic of a non-prescriptive aspect of cancer management.
The short essay question is designed to assess the students' knowledge and understanding across the breadth of all topics covered in the module.
A participation grade is included to encourage and reward the student's engagement with the
Should a student fail the participation assessment and have to undertake a re-sit they will have to complete a different form of assessment. The student will be asked to look at 2 participation activities as identified by the module leader/team and submit a 500 word written summary (approx. 250 words per activity).